These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 31710433)

  • 21. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
    Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
    Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
    van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
    J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary beta-glucuronidase activity as an initial screening test for urinary tract malignancy in high risk patients. Comparison with conventional urine cytologic evaluation.
    Ho KJ; Kuo SH
    Cancer; 1995 Aug; 76(3):473-8. PubMed ID: 8625129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
    Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
    BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.
    Kavalieris L; O'Sullivan PJ; Suttie JM; Pownall BK; Gilling PJ; Chemasle C; Darling DG
    BMC Urol; 2015 Mar; 15():23. PubMed ID: 25888331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer.
    Mazzone PJ; Wang XF; Lim S; Choi H; Jett J; Vachani A; Zhang Q; Beukemann M; Seeley M; Martino R; Rhodes P
    BMC Cancer; 2015 Dec; 15():1001. PubMed ID: 26698840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study.
    Morrissey JJ; Mellnick VM; Luo J; Siegel MJ; Figenshau RS; Bhayani S; Kharasch ED
    JAMA Oncol; 2015 May; 1(2):204-12. PubMed ID: 26181025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection.
    Wallace E; Higuchi R; Satya M; McCann L; Sin MLY; Bridge JA; Wei H; Zhang J; Wong E; Hiar A; Mach KE; Scherr D; Egerdie RB; Ohta S; Sexton WJ; Meng MV; Weizer AZ; Woods M; Jansz GK; Zadra J; Lotan Y; Goldfarb B; Liao JC
    J Urol; 2018 Mar; 199(3):655-662. PubMed ID: 29061538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
    Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
    J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer.
    Yang B; Liao GQ; Wen XF; Chen WH; Cheng S; Stolzenburg JU; Ganzer R; Neuhaus J
    J Zhejiang Univ Sci B; 2017 Nov.; 18(11):921-933. PubMed ID: 29119730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined use of epithelial membrane antigen and nuclear matrix protein 52 as sensitive biomarkers for detection of bladder cancer.
    Attallah AM; El-Far M; Abdallah SO; El-Waseef AM; Omran MM; Abdelrazek MA; Attallah AA; Saadh MJ; Radwan M; El-waffaey KA; Abol-Enei H
    Int J Biol Markers; 2015 Nov; 30(4):e407-13. PubMed ID: 26349665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematuria screening test for urinary bladder mucosal infiltration in cervical cancer.
    Chuttiangtum A; Udomthavornsuk B; Chumworathayi B
    Asian Pac J Cancer Prev; 2012; 13(10):4931-3. PubMed ID: 23244084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry.
    Nishiumi S; Kobayashi T; Kawana S; Unno Y; Sakai T; Okamoto K; Yamada Y; Sudo K; Yamaji T; Saito Y; Kanemitsu Y; Okita NT; Saito H; Tsugane S; Azuma T; Ojima N; Yoshida M
    Oncotarget; 2017 Mar; 8(10):17115-17126. PubMed ID: 28179577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue factor assays as diagnostic tools for cancer? Correlation between urinary and monocyte tissue factor activity.
    Lwaleed BA; Francis JL; Chisholm M
    J Hematother Stem Cell Res; 1999 Dec; 8(6):659-68. PubMed ID: 10645774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study.
    Ribal MJ; Mengual L; Lozano JJ; Ingelmo-Torres M; Palou J; Rodríguez-Faba O; Witjes JA; Van der Heijden AG; Medina R; Conde JM; Marberger M; Schmidbauer J; Fernández PL; Alcaraz A
    Eur J Cancer; 2016 Feb; 54():131-138. PubMed ID: 26761785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
    Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.
    Shariat SF; Casella R; Khoddami SM; Hernandez G; Sulser T; Gasser TC; Lerner SP
    J Urol; 2004 Feb; 171(2 Pt 1):626-30. PubMed ID: 14713774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
    Rogers CG; Yan G; Zha S; Gonzalgo ML; Isaacs WB; Luo J; De Marzo AM; Nelson WG; Pavlovich CP
    J Urol; 2004 Oct; 172(4 Pt 1):1501-3. PubMed ID: 15371879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary Cell-Free DNA Quantification as Non-Invasive Biomarker in Patients with Bladder Cancer.
    Brisuda A; Pazourkova E; Soukup V; Horinek A; Hrbáček J; Capoun O; Svobodova I; Pospisilova S; Korabecna M; Mares J; Hanuš T; Babjuk M
    Urol Int; 2016; 96(1):25-31. PubMed ID: 26338254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.